BUZZ-Viridian slides as Amgen data raises competition fears

Reuters04-06
BUZZ-Viridian slides as Amgen data raises competition fears

** Shares of drug developer Viridian Therapeutics VRDN.O fall 25.5% to $14.02

** Amgen AMGN.O says late-stage study showed its thyroid eye disease (TED) drug Tepezza was effective when given by subcutaneous injection to patients

** The trial met its main goal, with 76.7% of patients on subcutaneous Tepezza showing a significant reduction in eye bulging at 24 weeks, compared with 19.6% on placebo - AMGN

** Viridian shares had slumped 34% last week after its experimental TED drug lagged rivals on efficacy in a late‑stage trial, despite meeting its primary endpoint

** RBC Capital Markets says while Amgen appears to have an edge on efficacy, Viridian's elegrobart could still compete on convenience, requiring as few as four total subcutaneous injections over 24 weeks, compared with Tepezza’s on‑body injector, which delivers the drug every two weeks over the same period

** Including session's moves, VRDN down 51% YTD, while AMGN is up 5.9%

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment